Hematologic Malignancy
Myelodysplastic Syndrome
CI-CAN-00001247MDN · MDSExplore in graph →
Hematologic336 active trials3 approved drugs14 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001247MDN · MDSExplore in graph →
Clinical trials
1,702 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (307)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00299156 | Oral Clofarabine Study in Patients With Myelodysplastic Syndrome | completed | Phase 2 | 65 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 3, 2015 | clinicaltrials |
| NCT00134004 | Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer | completed | Phase 2 | 210 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 6, 2015 |
| clinicaltrials |
| NCT00086125 | Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED) | completed | Phase 2 | 57 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Aug 19, 2015 | clinicaltrials |
| NCT00588809 | Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Aug 5, 2015 | clinicaltrials |
| NCT00274781 | Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes | completed | Phase 2 | 30 | The Cleveland ClinicOTHER | 1 | Jul 10, 2015 | clinicaltrials |
| NCT00469729 | Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy(ExCell) | completed | Phase 2 / Phase 3 | 101 | Gamida Cell -Teva Joint Venture Ltd.OTHER | 5 | Jul 10, 2015 | clinicaltrials |
| NCT00324220 | A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia | completed | Phase 1 / Phase 2 | 66 | Mirati Therapeutics Inc.INDUSTRY | 1 | Jul 1, 2015 | clinicaltrials |
| NCT00954941 | Ondansetron Versus Aprepitant Plus Ondansetron for Emesis | completed | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 25, 2015 | clinicaltrials |
| NCT00034684 | Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701) | completed | Phase 1 / Phase 2 | 132 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 17, 2015 | clinicaltrials |
| NCT00673114 | Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies | completed | Phase 1 / Phase 2 | 3 | Joanne Kurtzberg, MDOTHER | 1 | Apr 3, 2015 | clinicaltrials |
| NCT01819558 | Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy(ALLO-WT1) | completed | Phase 1 / Phase 2 | 2 | Institut Paoli-CalmettesOTHER | 1 | Mar 20, 2015 | clinicaltrials |
| NCT00185796 | TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD | completed | Phase 2 | 77 | Stanford UniversityOTHER | 1 | Mar 18, 2015 | clinicaltrials |
| NCT00656617 | Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | completed | Phase 2 | 106 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 9, 2015 | clinicaltrials |
| NCT00016419 | S0020 Immunosuppressive Therapy in Treating Patients With Myelodysplastic Syndrome | completed | Phase 2 | 130 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00809276 | Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY | completed | Phase 1 / Phase 2 | 92 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 16, 2015 | clinicaltrials |
| NCT00589563 | Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer | completed | Phase 2 | 32 | City of Hope Medical CenterOTHER | 1 | Sep 10, 2014 | clinicaltrials |
| NCT00433745 | Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy | completed | Phase 2 | 4 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 8, 2014 | clinicaltrials |
| NCT00580034 | Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath | completed | Phase 2 | 176 | David Rizzieri, MDOTHER | 1 | Jun 3, 2014 | clinicaltrials |
| NCT00597714 | Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant | completed | Phase 2 | 264 | David Rizzieri, MDOTHER | 1 | Jun 2, 2014 | clinicaltrials |
| NCT00096122 | Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 95 | National Cancer Institute (NCI)NIH | 1 | May 26, 2014 | clinicaltrials |
| NCT00305773 | Vorinostat in Treating Patients With Acute Myeloid Leukemia | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | May 19, 2014 | clinicaltrials |
| NCT00003572 | Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers | completed | Phase 2 | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 2, 2014 | clinicaltrials |
| NCT00003960 | Donor Bone Marrow Transplantation in Treating Patients With Hematologic Cancer | completed | Phase 2 | 36 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 2, 2014 | clinicaltrials |
| NCT00003961 | Sargramostim After Bone Marrow Transplantation in Treating Patients With Myelodysplastic Syndrome | completed | Phase 2 | — | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 17, 2014 | clinicaltrials |
| NCT00004145 | Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer | completed | Phase 2 | 16 | University of ChicagoOTHER | 1 | Mar 7, 2014 | clinicaltrials |
| NCT00943592 | Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies | completed | Phase 1 / Phase 2 | 82 | University of ChicagoOTHER | 1 | Feb 27, 2014 | clinicaltrials |
| NCT00098683 | Amifostine in Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic Syndromes | completed | Phase 2 | 10 | Children's Oncology GroupNETWORK | 4 | Feb 13, 2014 | clinicaltrials |
| NCT00774046 | High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML | completed | Phase 2 | 32 | University of ChicagoOTHER | 1 | Feb 11, 2014 | clinicaltrials |
| NCT00066248 | Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment | completed | Phase 2 | 70 | University of South FloridaOTHER | 3 | Feb 3, 2014 | clinicaltrials |
| NCT00782379 | Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer | completed | Phase 2 | 20 | Northside Hospital, Inc.OTHER | 1 | Nov 21, 2013 | clinicaltrials |
| NCT00113893 | SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes. | completed | Phase 2 | 62 | Scios, Inc.INDUSTRY | 0 | Nov 7, 2013 | clinicaltrials |
| NCT01048034 | Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) | completed | Phase 2 | 30 | Nordic MDS GroupNETWORK | 3 | Oct 29, 2013 | clinicaltrials |
| NCT00977548 | Erlotinib Study for Myelodysplastic Syndrome (MDS) | completed | Phase 2 | 39 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 16, 2013 | clinicaltrials |
| NCT00882102 | Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS) | completed | Phase 2 | 43 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 13, 2013 | clinicaltrials |
| NCT00454480 | Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | completed | Phase 2 / Phase 3 | 2,000 | The University of New South WalesOTHER | 1 | Aug 26, 2013 | clinicaltrials |
| NCT00360672 | Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome | completed | Phase 2 | 27 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 14, 2013 | clinicaltrials |
| NCT00795132 | Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies | completed | Phase 2 | 47 | University of UtahOTHER | 1 | Jul 30, 2013 | clinicaltrials |
| NCT00054327 | Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer | completed | Phase 2 | 34 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2013 | clinicaltrials |
| NCT00083187 | VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia | completed | Phase 2 | 230 | Vion PharmaceuticalsINDUSTRY | 3 | Jul 18, 2013 | clinicaltrials |
| NCT00334074 | Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS | completed | Phase 2 | 30 | Baylor Research InstituteOTHER | 1 | Jul 17, 2013 | clinicaltrials |
| NCT00004255 | Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation | completed | Phase 2 / Phase 3 | — | Chimeric TherapiesINDUSTRY | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00002800 | Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome | completed | Phase 2 | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 3, 2013 | clinicaltrials |
| NCT00002502 | Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 27, 2013 | clinicaltrials |
| NCT00003361 | Decitabine in Treating Patients With Myelodysplastic Syndrome | completed | Phase 2 | 75 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 26, 2013 | clinicaltrials |
| NCT00003619 | Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | — | Drexel University College of MedicineOTHER | 1 | Jun 26, 2013 | clinicaltrials |
| NCT00053001 | Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome | completed | Phase 2 | — | Fallon ClinicINDUSTRY | 1 | Jun 26, 2013 | clinicaltrials |
| NCT00006019 | Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 24, 2013 | clinicaltrials |
| NCT00737516 | Centralized Cord Blood Registry to Facilitate Unrelated Cord Blood Transplantation | completed | Phase 2 | 3,621 | National Marrow Donor ProgramOTHER | 1 | Jun 21, 2013 | clinicaltrials |
| NCT00066599 | Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Jun 19, 2013 | clinicaltrials |
| NCT00195000 | Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS | completed | Phase 2 | 43 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 19, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Nov 3, 2015source: clinicaltrials